Press releases
10/12/2025
Equasens announces its 2026 financial agenda
05/11/2025
2025 Q3 revenue
26/09/2025
H1 2025 Results
31/07/2025
H1 revenue at 30 June 2025 : €116.0m
03/07/2025
Equasens announces the departure of Damien Valicon, as Deputy Chief Executive Officer and Director of the Pharmagest Division
01/07/2025
Results of the votes on the resolutions submitted to the Ordinary Annual Sharholders’ Meeting of 25 June 2025
30/06/2025
Equasens acquires DIS and ResUrgences businesses, strngthenning its position in the market of software solutions for healthcare establishments
06/06/2025
Annual Ordinary General Meeting – Meeting Notice and On-line availability of meeting materials
12/05/2025
Q1 2025 Revenue
30/04/2025
Exclusive negotiations initiated with a French software editor to acquire twa software publishing businesses operating in the public health sector
28/03/2025
2024 Annual results
06/02/2025
2024 FY Revenues
27/12/2024
Equasens strengthens its presence in the healthcare software marketwith the strategic acquisition of Calimed
25/11/2024
Equasens Group and Posos join forces to transform pharmacy dispensing processes through innovative artificial intelligence
25/11/2024
DIGIPHARMACIE becomes an official partner dematerialization platform (PDP)
07/11/2024
2024 Q3 Revenues
27/09/2024
H1 2024 RESULTS
02/08/2024
2024 H1 Revenue
05/07/2024
Results of the votes on the resolutions submitted to the Ordinary Annual Shareholders’ Meeting of 27 June 2024
10/06/2024
Annual Ordinary General Meeting – Meeting Notice and On-line availability of meeting materials
07/05/2024
2024 Q1 REVENUE
29/03/2024
2023 ANNUAL RESULTS
06/02/2024
2023 FY REVENUE
02/01/2024
Acquisition of a majority stake in DIGIPHARMACIE
27/12/2023
Change in executive committee
09/11/2023
Q3 2023 REVENUE
03/08/2023
H1 2023 revenue
05/07/2023
Results of the votes on the resolutions submitted to the Ordinary Annual Shareholders’ Meeting of 29 June 2023
09/06/2023
Annual Ordinary General Meeting – Meeting Notice and On-line availability of meeting materials
11/05/2023
Q1 2023 revenue: +13.96% to €56.25m
03/04/2023
Equasens Group’s Medical Solutions Division is reinforced by the addition of Pratilog and Speech2Sense
24/03/2023
2022 NET PROFIT: +18.35% TO €48.70M
03/02/2023
FY 2022 revenue: +10.88% to €214.07m
20/01/2023
H2 2022 Half-year report on the liquidity agreement with the brokerage firm Gilbert Dupont
19/01/2023
Appointment of Frédérique SCHMIDT as the Group’s Chief Administrative and Financial Officer
09/11/2022
2022 third-quarter revenue
18/10/2022
PANDALAB receives ISO 27001 and HDS certifications
22/09/2022
H1 2022 Results
03/08/2022
H1 2022 Revenue
28/07/2022
Equasens Group completes three majority acquisitions
21/07/2022
H1 2022 Half-year report on the liquidity agreement with the brokerage firm Gilbert Dupont
06/07/2022
Results of the votes on the resolutions submitted to the Ordinary Annual Shareholders’ Meeting of 28 June 2022
27/06/2022
EQUASENS joins Euronext’s new TECH LEADERS segment
15/06/2022
EQUASENS changes its ticker code to become EQS
10/06/2022
Annual Ordinary General Meeting – Meeting Notice and On-line availability of meeting materials
30/05/2022
Annual Ordinary General Meeting – Preliminary Notice
12/05/2022
Q1 2022 revenue: +9.03% to €49.36m
10/05/2022
